These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31115606)

  • 1. Long non-coding RNA GHET1 contributes to chemotherapeutic resistance to Gemcitabine in bladder cancer.
    Li B; Xie D; Zhang H
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):187-194. PubMed ID: 31115606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long noncoding RNA NORAD acts as a ceRNA mediates gemcitabine resistance in bladder cancer by sponging miR-155-5p to regulate WEE1 expression.
    Yang Y; Zhang G; Li J; Gong R; Wang Y; Qin Y; Ping Q; Hu L
    Pathol Res Pract; 2021 Dec; 228():153676. PubMed ID: 34753061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells.
    Zhang X; Taoka R; Liu D; Matsuoka Y; Tohi Y; Kakehi Y; Sugimoto M
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long non-coding RNA GHET1 promotes human breast cancer cell proliferation, invasion and migration via affecting epithelial mesenchymal transition.
    Song R; Zhang J; Huang J; Hai T
    Cancer Biomark; 2018; 22(3):565-573. PubMed ID: 29843220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells.
    Pan J; Li X; Wu W; Xue M; Hou H; Zhai W; Chen W
    Cancer Lett; 2016 Nov; 382(1):64-76. PubMed ID: 27591936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of lncRNA GHET1 inhibits osteosarcoma cells proliferation, invasion, migration and EMT in vitro and in vivo.
    Yang W; Shan Z; Zhou X; Peng L; Zhi C; Chai J; Liu H; Yang J; Zhang Z
    Cancer Biomark; 2018; 23(4):589-601. PubMed ID: 30475755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-129-5p inhibits gemcitabine resistance and promotes cell apoptosis of bladder cancer cells by targeting Wnt5a.
    Cao J; Wang Q; Wu G; Li S; Wang Q
    Int Urol Nephrol; 2018 Oct; 50(10):1811-1819. PubMed ID: 30117016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143.
    An Q; Zhou L; Xu N
    Biomed Pharmacother; 2018 Jul; 103():415-420. PubMed ID: 29674277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Long Noncoding RNA HOST2 Promotes Gemcitabine Resistance in Human Pancreatic Cancer Cells.
    An N; Cheng D
    Pathol Oncol Res; 2020 Jan; 26(1):425-431. PubMed ID: 30406400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of long non-coding RNA GHET1 promotes the development of multidrug resistance in gastric cancer cells.
    Zhang X; Bo P; Liu L; Zhang X; Li J
    Biomed Pharmacother; 2017 Aug; 92():580-585. PubMed ID: 28578256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long noncoding RNA GHET1 promotes the development of bladder cancer.
    Li LJ; Zhu JL; Bao WS; Chen DK; Huang WW; Weng ZL
    Int J Clin Exp Pathol; 2014; 7(10):7196-205. PubMed ID: 25400817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long noncoding RNA GHET1 promotes cell proliferation through oxidative stress in prostate cancer.
    Wen Y; Huang H; Huang B; Liao X
    J Biochem Mol Toxicol; 2023 Jul; 37(7):e23369. PubMed ID: 37029520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Berberine enhances gemcitabine‑induced cytotoxicity in bladder cancer by downregulating Rad51 expression through inactivating the PI3K/Akt pathway.
    Gao X; Liu J; Fan D; Li X; Fang Z; Yan K; Fan Y
    Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34935059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA SNHG8 promotes the development and chemo-resistance of pancreatic adenocarcinoma.
    Song Y; Zou L; Li J; Shen ZP; Cai YL; Wu XD
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8161-8168. PubMed ID: 30556854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and clinical significance of long-non-coding RNA GHET1 in pancreatic cancer.
    Zhou HY; Zhu H; Wu XY; Chen XD; Qiao ZG; Ling X; Yao XM; Tang JH
    Eur Rev Med Pharmacol Sci; 2017 Nov; 21(22):5081-5088. PubMed ID: 29228419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYLD downregulates Livin and synergistically improves gemcitabine chemosensitivity and decreases migratory/invasive potential in bladder cancer: the effect is autophagy-associated.
    Yin L; Liu S; Li C; Ding S; Bi D; Niu Z; Han L; Li W; Gao D; Liu Z; Lu J
    Tumour Biol; 2016 Sep; 37(9):12731-12742. PubMed ID: 27448305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulated Long Noncoding RNA PART1 Inhibits Proliferation and Promotes Apoptosis in Bladder Cancer.
    Hu X; Feng H; Huang H; Gu W; Fang Q; Xie Y; Qin C; Hu X
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819846638. PubMed ID: 31311442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of effect of lncRNA MVIH on sensitivity of gastric cancer cells to gemcitabine.
    Xu HF; Shi DM; Zhu XQ
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(21):9651-9659. PubMed ID: 31773716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer.
    Kerr M; Scott HE; Groselj B; Stratford MR; Karaszi K; Sharma NL; Kiltie AE
    Clin Cancer Res; 2014 Nov; 20(21):5435-45. PubMed ID: 25224279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.